Enjoy complimentary customisation on priority with our Enterprise License!
According to this insulin market analysis, insulin market in the US and Europe will grow at a CAGR of more than 6% by 2020. The insulin market is witnessing several developments pertaining to product portfolio and delivery technologies, which has increased the life expectancy of individuals with diabetes. The demand for automated injection devices such as insulin pumps and pens are increasing at a high rate as they offer safe and easy drug delivery options. Vendors are also coming up with implantable insulin pumps that will release the exact amount of insulin in the body by detecting the blood glucose level. Such advancements in insulin delivery methodologies will boost the growth of the European and US insulin market size during the next few years.
Besides developing new insulin-based products, several pharmaceutical companies are coming up with drugs based on different therapeutic approaches to treat diabetes. For instance, Diabecel is a cell therapy-based product that secretes insulin on detecting the elevated glucose levels. Similarly, DV-100 is a diabetes vaccine that restricts the body's autoimmunity action against pancreatic islet cells and modulates the immune system. The recent increase in research activities for novel products will aid in the growth of the insulin market size in the US and Europe during the forecast period.
Based on the insulin market analysis, Type 2 diabetes is the largest segment of the global insulin market in terms of application and occupied around 90% of the total insulin market share during 2015. Type 2 diabetes is a chronic metabolic condition caused by lifestyle and genetic factors. In such a condition, the absorption of glucose into cells is very low, which increases the blood glucose levels and progressively damages nerves and blood vessels, resulting in the starvation of the cells. Growing incidences of Type 2 diabetic condition will propel the demand for insulin over the next few years.
US insulin market share is about 77% of the insulin market and is expected to grow significantly until 2020 owing to the growing number of individuals with diabetes. Better accessibility to treatment therapies and the presence of favorable reimbursement programs will result in the high turnout of patients opting for diabetes treatment. This will, in turn, fuel the growth of the US insulin market size during the next few years.
This insulin market is primarily dominated by the large multinational players who account for a major part of the total market share. According to this insulin market analysis, the vendors are undergoing strategic alliances to promote and manufacture their drug offerings and the insulin industry will witness the entry of new players during the forecast period owing to the patent expiries for existing drugs.
Key vendors in the market are
Other prominent vendors in the Europe and US insulin industry include Adocia, Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Dance Biopharm, Diasome Pharmaceuticals, Exsulin, Generex, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, MannKind, Macrogenics, Merck, Melior Pharmaceuticals, Metabolic Solutions Development Company, NGM Biopharmaceuticals, NuSirt Biopharma, Oramed Pharmaceuticals, PhaseBio Pharmaceuticals, Pfizer, Thermalin Diabetes, Tolerion, VeroScience, vTv Therapeutics, Wockhardt, and XOMA.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Major branded drug profiles
PART 06: Insulin: An overview
PART 07: Pipeline portfolio
PART 08: Oral insulin therapies
PART 09: Market landscape
PART 10: Market segmentation by drug class
PART 11: Market segmentation by application
PART 12: Market segmentation by insulin delivery technologies
PART 13: Geographical segmentation
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
PART 20: Appendix
PART 21: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.